Form 4: Cullinan Therapeutics' Chief Scientific Officer Receives Stock Options and Restricted Stock Units

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, acquired 50,000 shares of common stock and stock options for 100,000 shares on February 19, 2025.

Summary

• Jennifer Michaelson, the Chief Scientific Officer of Cullinan Therapeutics, Inc., filed a Form 4 on February 21, 2025.
• On February 19, 2025, she acquired 50,000 shares of common stock and stock options for 100,000 shares.
• The common stock was acquired at a price of $0.
• The stock options have an exercise price of $9.43 and expire on February 19, 2035.
• The shares underlying the restricted stock units vest annually over four years.
• The shares underlying the options vest over four years, with 1/48th vesting monthly until the fourth anniversary of the grant date.
• Following the transaction, Michaelson directly owns 145,760 shares of common stock and options for 100,000 shares.
• The filing was signed by Jacquelyn Sumer, Attorney-in-Fact, on February 21, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of shares and options by the CSO could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock and options by a key executive could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the Chief Scientific Officer.

Key Dates

Keywords

Form 4, Cullinan Therapeutics, Jennifer Michaelson, Stock Options, Restricted Stock Units, Beneficial Ownership, CGEM